Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 30, 2012PharmaceuticalsOpen Access

On the Regulatory Approval Pathway of Biosimilar Products

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJun WangSCShein‐Chung Chow

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2012) studied this question.

synapsesocial.com/papers/6a830bd7c009eb9b7eefe0d7https://doi.org/10.3390/ph5040353
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics2011 · 35 citations
  2. 2Regulatory guideline for biosimilar products in Korea2011 · 21 citations
  3. 3Worldwide experience with biosimilar development2011 · 200 citations